Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen

NCT00358540 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00358540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00358540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2006
Completion date
October 22, 2010
Enrollment
18 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocytopaenia